Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors.

Molecular pharmacology - 1 Dec 2016

Pajor Ana M, de Oliveira Cesar A, Song Kun, Huard Kim, Shanmugasundaram Veerabahu, Erion Derek M

Abstract excerpt

The Na+/citrate transporter, NaCT (SLC13A5), is a therapeutic target for metabolic diseases. Citrate is an important signaling molecule that regulates the activity of lipid- and glucose-metabolizing enzymes in cells. Previous studies identified two compounds, PF-06649298 (compound 2: ) and PF-06678419 (compound 4: ), that inhibit human NaCT with high affinity, and one of the compounds demonstrated specificity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Transport
Share to Citric Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Molecular Docking Simulation

Share to Mutant Proteins

Share to Sodium

Share to Structural Homology, Protein

Share to Vibrio cholerae

Source

Identifiers

PMID: 27683012
DOI: 10.1124/mol.116.105049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors.PMID 27683012Read ↗

Targeting an allosteric binding site in the citrate transporter NaCT (SLC13A5)Semantic proximity Read ↗

Functional analysis of a species-specific inhibitor selective for human Na+-coupled citrate transporter (NaCT/SLC13A5/mINDY)Semantic proximity Read ↗

Structure and inhibition mechanism of the human citrate transporter NaCT.Semantic proximity Read ↗

Role of Sodium dependent SLC13 transporter and its inhibitors in various metabolic disordersSemantic proximity Read ↗

A home run for human NaCT/SLC13A5/INDY: cryo-EM structure and homology model to predict transport mechanisms, inhibitor interactions and mutational defects.Semantic proximity Read ↗

Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.Semantic proximity Read ↗

Functional Distinction between Human and Mouse Sodium-Coupled Citrate Transporters and Its Biologic Significance: An Attempt for Structural Basis Using a Homology Modeling ApproachSemantic proximity Read ↗

A cell-based method to assess the activity of the human sodium-coupled citrate transporterSemantic proximity Read ↗

Molecular phenotypes segregate missense mutations in SLC13A5 EpilepsySemantic proximity Read ↗

Large-scale experimental assessment of variant effects on the structure and function of the citrate transporter SLC13A5Semantic proximity Read ↗

Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay.Semantic proximity Read ↗

The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.